Education
About Us
Working with TipRanks
Follow Us
Carisma Therapeutics, Inc. (CARM)
:CARM
CARM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.14 - $1.27
Previous CloseN/A
Volume72.54K
Average Volume (3M)16.94M
Market Cap
$16.79M
Enterprise Value$16.07M
Total Cash (Recent Filing)$2.00M
Total Debt (Recent Filing)$1.70M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Nov 06, 2025EPS Estimate
-0.12Last Dividend Ex-Date
Mar 08, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding41,788,097
10 Day Avg. Volume49,961,803
30 Day Avg. Volume16,943,161
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue1.49
Enterprise Value/Gross Profit1.65
Enterprise Value/Ebitda-0.38
Forecast
1Y Price Target
$0.50Price Target Upside25.00% Upside
Rating ConsensusHold
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe mesothelin targeted autologous CAR monocyte program is expected to show evidence of clinical responses and clean safety, which should de-risk and validate the monocyte platform.
Strategic PartnershipsCarisma will focus on developing off-the-shelf products using its in vivo macrophage engineering platform, including those under the Moderna partnership.
Bears Say
Program DiscontinuationCarisma Therapeutics announced that it would be discontinuing development of its lead program, CT-0525.
Workforce ReductionAs part of the strategic restructuring, Carisma will reduce its workforce by 34%.
Carisma Therapeutics News
CARM FAQ
What was Carisma Therapeutics, Inc.’s price range in the past 12 months?
Carisma Therapeutics, Inc. lowest stock price was $0.14 and its highest was $1.27 in the past 12 months.
What is Carisma Therapeutics, Inc.’s market cap?
Carisma Therapeutics, Inc.’s market cap is $16.79M.
When is Carisma Therapeutics, Inc.’s upcoming earnings report date?
Carisma Therapeutics, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 57 days.
How were Carisma Therapeutics, Inc.’s earnings last quarter?
Carisma Therapeutics, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of -$0.09 by -$0.14.
Is Carisma Therapeutics, Inc. overvalued?
According to Wall Street analysts Carisma Therapeutics, Inc.’s price is currently Undervalued.
Does Carisma Therapeutics, Inc. pay dividends?
Carisma Therapeutics, Inc. pays a Notavailable dividend of $0.361 which represents an annual dividend yield of N/A. See more information on Carisma Therapeutics, Inc. dividends here
What is Carisma Therapeutics, Inc.’s EPS estimate?
Carisma Therapeutics, Inc.’s EPS estimate is -0.12.
How many shares outstanding does Carisma Therapeutics, Inc. have?
Carisma Therapeutics, Inc. has 41,788,097 shares outstanding.
What happened to Carisma Therapeutics, Inc.’s price movement after its last earnings report?
Carisma Therapeutics, Inc. reported an EPS of -$0.23 in its last earnings report, missing expectations of -$0.09. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Carisma Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CARM
Carisma Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$0.50 (25.00% Upside)
$0.50 (25.00% Upside)
Blogger Sentiment
Bullish
CARM Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▲ 8.9%
Last 30 Days ▲ 5.5%
Last 30 Days ▲ 5.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.30%
12-Months-Change
Fundamentals
Return on Equity
-362.79%
Trailing 12-Months
Asset Growth
-91.55%
Trailing 12-Months
Company Description
Carisma Therapeutics, Inc.
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
Technical Analysis
Kiora Pharmaceuticals
―
Dogwood Therapeutics
―
Acurx Pharmaceuticals
―
Conduit Pharmaceuticals
―
Turnstone Biologics Corp.
―
Ownership Overview
1.16%
Insiders
4.10% Mutual Funds
5.62% Other Institutional Investors
88.23% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---